Using apolipoprotein B to manage dyslipidemic patients: time for a change?
Harper
Charles R
CR
Department of Medicine, Emory University, 49 Jesse Hill Junior Drive SE, Atlanta, GA 30303, USA. charper@emory.edu
Jacobson
Terry A
TA
D001055:Apolipoproteins B / Q000097:blood*; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000097:blood; D050171:Dyslipidemias / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D011237:Predictive Value of Tests; D012307:Risk Factors
D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors